Pharmacoeconomic review report : Sebelipase Alfa (Kanuma) (Alexion pharmaceuticals, Inc.)

Pharmacoeconomic review report Sebelipase Alfa (Kanuma) (Alexion pharmaceuticals, Inc.)

Sebelipase alfa (Kanuma) is a recombinant form of the human lysosomal acid lipase (LAL) enzyme, and is indicated for the treatment of infants, pediatric, and adult patients diagnosed with LAL deficiency. The recommended starting dose in infants (less than six months of age) presenting with rapidly p...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : CADTH 2018.
Materias:
Medicine > Research.
Cost effectiveness.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820267906719
Tabla de Contenidos:
  • Abbreviations
  • Executive Summary
  • Background
  • Summary of Identified Limitations and Key Results
  • Conclusions
  • Information on the Pharmacoeconomic Submission
  • Summary of the Manufacturer's Pharmacoeconomic Submission
  • Manufacturer's Base Case
  • Summary of Manufacturer's Sensitivity Analyses
  • Limitations of Manufacturer's Submission
  • CADTH Common Drug Review Reanalyses
  • Patient Input
  • Conclusions
  • Appendix 1. Cost Comparison
  • Appendix 2. Summary of Key Outcomes
  • Appendix 3. Additional Information
  • Appendix 4. Summary of Other HTA Reviews of Drug
  • Appendix 5. Reviewer Worksheets
  • References.

Ejemplares similares